How many drugs treat Gonorrhea of pharynx?

Drug Landscape tracks 10 marketed treatments for Gonorrhea of pharynx (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/gonorrhea-of-pharynx.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gonorrhea of pharynx — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gonorrhea of pharynx (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gonorrhea of pharynx, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Minocycline Hydrochloride	MINOCYCLINE	Rempex	Tetracycline-class Drug		1971-01-01
Vibramycin	doxycycline	Generic (originally Pfizer)	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Demethylchlortetracycline	DEMECLOCYCLINE	Pfizer	Tetracycline-class Antimicrobial	Estrogen receptor beta	1960-01-01
Minocyclin	Minocyclin	University of Southern California		30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B
Meclan	MECLOCYCLINE	Johnson And Johnson	meclocycline
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
ENOXA®	ENOXA®	Les Laboratoires des Médicaments Stériles		RISC-loading complex subunit TARBP2, V-type proton ATPase subunit B, brain isoform, DNA gyrase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Gonorrhea of pharynx
Astellas Pharma · 1 drug in Gonorrhea of pharynx
Bulovka Hospital · 1 drug in Gonorrhea of pharynx
Centre Hospitalier Universitaire Vaudois · 1 drug in Gonorrhea of pharynx
GSK · 1 drug in Gonorrhea of pharynx
Generic (originally Pfizer) · 1 drug in Gonorrhea of pharynx
Generic (originally Roche) · 1 drug in Gonorrhea of pharynx
Johnson And Johnson · 1 drug in Gonorrhea of pharynx
Les Laboratoires des Médicaments Stériles · 1 drug in Gonorrhea of pharynx
Pfizer · 1 drug in Gonorrhea of pharynx
Rempex · 1 drug in Gonorrhea of pharynx
University of Southern California · 1 drug in Gonorrhea of pharynx

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gonorrhea of pharynx:

Cite this brief

Drug Landscape (2026). Gonorrhea of pharynx — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gonorrhea-of-pharynx. Accessed 2026-06-10.

Gonorrhea of pharynx full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing